• ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US
No announcement available or all announcement expired.
NSCI (LON) 6,00 GBX
  • ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US

Key patent granted for Glucosense’s technology

Jul 15, 2015
-
News, RNS Announcements
RNS Number : 0582T
NetScientific PLC
15 July 2015

 

 

NetScientific plc

 

Significant European patent granted on Glucosense Diagnostics technology

 

 

London, UK – 15 July 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, highlights University of Leeds’ announcement about its jointly funded portfolio company, Glucosense Diagnostics (Glucosense). Today the award of the first critical European patent covering Glucosense’s core technology is also announced – marking a significant milestone for the company.

 

Glucosense is developing a fully non-invasive device to measure the real-time blood glucose levels of people living with diabetes. It could provide a simpler, pain-free and more cost effective alternative to the traditional finger-pricking test.

 

The technology uses nano-engineered silica glass with ions that fluoresce when stimulated by a low power laser. When the glass is in contact with the user’s skin, the extent of the fluorescent signal varies in relation to the concentration of glucose in their blood – enabling a direct measurement of glucose levels.

 

Initial clinical testing of a prototype device showed a clinically acceptable accuracy rate of 96.5% indicating that the device has the potential to be at least as accurate as current methods. Further device development is underway which will be followed by more clinical studies.

 

David Gough, Chairman of Glucosense Diagnostics and NetScientific’s Head of European Investments and Operations, commented: “Glucosense’s technology has the potential to transform the lives of millions of people by providing a way to monitor blood glucose without the need for a needle. We hope people will be encouraged to regularly monitor themselves as a finger-touch rather than finger-prick test is far more appealing. Better self-regulation would help minimise related health complications and emergency hospital treatments.

 

“The award of an important European patent for Glucosense’s laser technology is a significant step in preparing the ground for commercial launch within the next three years. We are developing a non-invasive continuous monitoring wearable which may replace implanted devices for people with the severe Type I diabetes; it will also help people with lifestyle induced Type 2 diabetes – a much larger and rapidly growing population.”

 

-Ends-

 

The University of Leeds announcement can be found here: http://www.leeds.ac.uk/news/30292/press_releases

 

About diabetes

Diabetes is a growing global problem. Over 380 million people are estimated to have diabetes at a cost of $500bn to healthcare providers. By 2035, this number is expected to rise to nearly 600 million adults worldwide. People with diabetes need to regularly measure their blood glucose levels up to 5-8 times a day. Currently, this is done by finger-pricking with a needle – a process that is uncomfortable and messy. As a result, many people do not test themselves as often as they should.

 

About NetScientific

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net. 

 

About Glucosense

Glucosense is a NetScientific portfolio company jointly formed and initially funded by the University of Leeds and NetScientific plc. It is developing a non-invasive blood glucose monitoring device which could greatly improve the lives of people living with diabetes. The technology’s nano-engineered silica glass is used with a low-powered laser to provide real-time measurements of the concentration of glucose in blood. The device has the promise of becoming the first non-invasive way to measure glucose levels, providing a simpler, pain-free and potentially cheaper alternative to the current finger-pricking method. It also has continuous monitoring capabilities making it ideal to be developed as a wearable hypoglycaemia-alert device and replacement for the implantable continuous glucose monitoring device that some people living with Type 1 diabetes require. 

www.glucosense.net 

 

About University of Leeds

The University of Leeds is one of the largest higher education institutions in the UK, with more than 31,000 students from 147 different countries, and a member of the Russell Group research-intensive universities.

We are a top 10 university for research and impact power in the UK, according to the 2014 Research Excellence Framework, and positioned as one of the top 100 best universities in the world in the 2014 QS World University Rankings. 

www.leeds.ac.uk
 

Contact Details

 

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

PFUSFIFMLFISEIW

FacebookTweetLinkedin
← PREVIOUS POST
ProAxsis launches first-in-class ProteaseTag™ test
NEXT POST →
Results of Annual General Meeting
News
  • Glycotest receives 2nd $3m tranche of $10m finance
  • Appointment to the Board
  • PDS collaborates with Merck in Phase 2 studies
  • PDS prioritise PDS0101 in High risk HPV to Phase 2
  • PDS – positive data for immunotherapy treatment
INVESTORS
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • Corporate Governance
  • News
Categories
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
Archives
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

NetScientific plc

PO Box 76075
London
EC3P 3DX

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • Corporate Governance
  • News
copyright
Terms of Use
Key patent granted for Glucosense's technology - NetScientific